Loading organizations...

§ Venture Capital · Taipei, Fujian, China
Venture capital firm providing funding and strategic support for businesses across various sectors, focused on long-term growth.
Eminent Venture Capital Corporation specializes in commercializing intangible assets within biotechnology and medical sectors. It provides comprehensive services including intellectual property management, technology transfer, and patent licensing. The firm integrates financial investment with strategic advisory, effectively transitioning scientific innovations into viable market solutions.
Established in 2002 by a team experienced in biotech and medical investment, the firm began as a technical advisory company. This foundation stemmed from insight into the need for specialized guidance to commercialize complex intellectual property. Eminent Venture Capital Corporation later expanded, managing venture funds, including ChiHang II Venture Capital.
The firm targets startups and growing enterprises rich in intellectual property across the biotech and medical industries. Its vision is to accelerate innovation by providing strategic capital and expert support for advanced technology development. Eminent Venture Capital Corporation fosters an ecosystem where scientific breakthroughs become impactful commercial solutions.
Eminent II Venture Capital has 2 tracked investments across 2 companies. The latest tracked deal is $12.5M Series B in ACT Genomics in May 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 6, 2016 | ACT Genomics | $12.5M Series B | Cdib Capital, Hotung Venture Group | HUA NAN Venture Capital, President International Development Corporation, UMC Capital |
| Aug 9, 2007 | Nereus Pharmaceuticals | $45.0M Series D | Bankinvest Biomedical Venture | Advent International, Alta Partners, Astellas Venture Management, Boston Life Science Venture Corporation, Forward Ventures, GIMV, HBM Healthcare Investments, Interwest Partners, Pacific Venture Group, Roche, Taiwan Global Biofund |